Author

M. H. Malim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1

Frequent Co-Authors

K. J. Doores· 5 shared C. Graham· 4 shared J. Seow· 3 shared A. Kurshan· 2 shared A. Waters· 2 shared C. Mant· 2 shared I. Huettner· 2 shared J. Fox· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

K. J. Doores

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

J. Seow, Z. A. Shalim, C. Graham, S. Kimuda, A. Pillai, T. Lechmere, A. Kurshan, A. Khimji, L. Snell, G. Nebbia, C. Mant, A. Waters, J. Fox, M. H. Malim, K. J. Doores

The paper shows that vaccinated individuals develop broad neutralizing mAbs after Delta/BA.1 infection, but these mAbs are less effective against newer variants.

bioRxiv · Mar 30, 2023 · PreprintImmunology

Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5

B. J. Willett, A. Kurshan, N. Thakur, J. Newman, M. Manali, G. Tyson, N. Logan, P. R. Murcia, L. B. Snell, J. D. Edgeworth, J. Zhou, K. Sukhova, G. Amirthalingam, K. Brown, B. Charleston, , T. P. Peacock

This study compares the antigenic properties of SARS-CoV-2 Omicron variants BA.4 and BA.5 with BA.1, BA.2, and vaccine-induced antibodies, finding they are antigenically distinct and show enhanced neutralisation breadth after breakthrough infection.

bioRxiv · May 25, 2022 · PreprintMicrobiology

Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2

M. D. J. Dicks, L. M. Rose, L. A. H. Bowman, C. Graham, K. J. Doores, M. H. Malim, S. J. Draper, M. Howarth, S. Biswas

This paper describes a method to enhance adenovirus vaccine efficacy by decorating capsid surfaces with antigens, resulting in improved humoral immunity and retained T cell responses.

bioRxiv · Feb 20, 2022Bioengineering

MX2 viral substrate breadth and inhibitory activity are regulated by protein phosphorylation

G. Betancor, M. E. M. Bangham, J. K. Jeon, K. Sha, S. Lynham, J. M. Jimenez Guardeno, M. H. Malim

This paper identifies key phosphorylation sites in MX2 that regulate its antiviral activity and substrate specificity, showing that hypermorphic mutants can inhibit HIV-1 and resistant retroviruses.

bioRxiv · Jan 24, 2022Microbiology

ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants

J. Seow, C. Graham, S. R. Hallett, T. Lechmere, T. J. A. Maguire, I. Huettner, D. Cox, R. Roberts, A. Waters, C. C. Ward, C. Mant, M. J. Pitcher, J. Spencer, J. Fox, M. H. Malim, K. J. Doores

This study isolates monoclonal antibodies from a vaccinated individual and shows they neutralize multiple SARS-CoV-2 variants effectively.

bioRxiv · Sep 27, 2021Immunology

Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12

J. M. Jimenez-Guardeno, A. M. Ortega-Prieto, B. Menendez Moreno, T. J. A. Maguire, A. Richardson, J. I. Diaz Hernandez, J. Diez Perez, M. Zuckerman, A. Mercadal Playa, C. Cordero Deline, M. H. Malim, R. T. Martinez-Nunez

This paper compares a quantum-inspired method and traditional fingerprinting to repurpose drugs against SARS-CoV-2, identifying vitamin B12 and BMS-986094 as potential antivirals effective against multiple variants.

bioRxiv · Jun 25, 2021 · PreprintMicrobiology

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

C. Graham, J. Seow, I. Huettner, H. Khan, N. Kouphou, S. Acors, H. Winstone, S. Pickering, R. Pedro Galao, M. Jose Lista, J. M. Jimenez-Guardeno, A. G. Laing, Y. Wu, M. Joseph, L. Muir, , K. J. Doores

This study examines how mutations in the B.1.1.7 variant of SARS-CoV-2 affect neutralization by monoclonal antibodies targeting non-RBD epitopes.

bioRxiv · Feb 3, 2021 · PreprintImmunology